Usually when an industry gets a booming industry it is largely due to profitability, which garners interest from investors.
But in biotech there is a section of the industry that is gaining investors and various firms chasing a similar goal. However, how that is happening is a mystery. The companies are burning through millions, hasn’t started clinical work on a drug candidate and it will be years, “if ever” before it has something commercializable.
What industry am I referring to? CRISPR-Cas9 technology. We’ve talked on the blog before about the possibilities CRISPR has to offer human health, but over at The Economist here’s a post about whether or not it can be all we dream it to be.